International ophthalmic company Nicox (Euronext Paris: COX) has entered into an exclusive licensing agreement with Australian company OptiMed for the distribution of its product portfolio in Australia and New Zealand.
This is the latest step in Nicox’s international operations, and the company has third-party agreements already established in Japan, Switzerland, Belgium, the Netherlands, Luxemburg, Poland Turkey and countries in southern Africa.
The deal with OptiMed will cover, among other products, Nicox’s AdenoPlus and the Xailin range.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze